Skip to main content
Log in

Novelty in the target landscape of the pharmaceutical industry

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Percentage of targets by competitive space.
Figure 2: Competition on novel targets by latest development phase.
Figure 3: Novel targets across the 10 largest pharmaceutical companies.

References

  1. DiMasi, J. A. & Faden, L. B. Competitiveness in follow-on drug R&D: a race or imitation? Nature Rev. Drug Discov. 10, 23–27 (2011).

    Article  CAS  Google Scholar 

  2. Agrawal, V. & Jamwal, S. Top ten global pharma. World Pharmaceutical Frontiers [online], (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pankaj Agarwal.

Ethics declarations

Competing interests

The authors are all employeees of GlaxoSmithKline.

Related links

FURTHER INFORMATION

Pharmaprojects

PowerPoint slides

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwal, P., Sanseau, P. & Cardon, L. Novelty in the target landscape of the pharmaceutical industry. Nat Rev Drug Discov 12, 575–576 (2013). https://doi.org/10.1038/nrd4089

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4089

  • Springer Nature Limited

This article is cited by

Navigation